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Oral Presentations S163suggesting an association between GvHD clinical course and CD41
T-cell imbalance. In accordance with the decrease of Th1 CD41 T
cells in the PB of CR patients, we observed a valuable decrease of
IFNg plasma concentrations, which reached the levels typical of
HD. Contrary to CR patients, in PR patients we observed a transient
decrease of GVHD plasmatic markers and Th1/Treg, Th17/Treg
ratios, while NR patients showed stable or even increasing levels of
all analysed plasmatic and cellular markers.
In summary, despite its limited size, the present study suggests
that MSCs, upon infusion, are able to convert an inflammatory envi-
ronment to a more physiological one, both at a cellular level, pro-
moting the expansion of circulating Tregs, and at a molecular
level, diminishing inflammatory cytokines.31
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GvHD is a major problem in allogeneic hematopoietic cell trans-
plantation (HCT) fom unrelated donors (UD). In our prospective
randomized multicenter trial we could show the efficacy of addi-
tional ATG-F to standard GvHD prophylaxis with cyclosporine A
and Mtx in reducing all grades of acute and chronic GvHD without
negatively affecting NRM, relapse rate or DFS in 201 adult patients
(median age 40 (range 18-60) years) with leukemia or MDS in early
(n 5 107) and advanced (n 5 94) disease transplanted after myeloa-
blative conditioningwithmarrow (n5 37) or blood (n5 134). (Finke
et al., Lancet Oncol, 2009).
Risk factors for the outcome after UD-HCT have been postulated
from retrospective analyses of registry data, however data from ran-
domized trials are lacking.With an extended follow of median 3 years
we present mature data on outcome and multivariate analysis of risk
factors: Incidence of grade III-IV aGvHD was 11.7% in the ATG-F
group and 25.5% in the control group (p 5 0.039), the incidence of
extensive chronicGvHD (cGvHD) after three years was 12.2% versus
45.0% (p\0.0001),DFSwas 48.0%and 38.4%, (p5 0.71), incidence
of relapse was 32.6% and 28.2% (p 5 0.47), incidence of NRM was
19.4% and 33.5% (p 5 0.18), and OS was 55.2% and 43.3% in the
ATG-F and control groups, respectively (p 5 0.39).
The following factors were analyzed with regard to OS, DFS,
risk of relapse, aGvHD III/IV, extensive cGvHD and NRM: pa-
tient age ([. /\ ] 40 y), donor age (. /\ ] 40 y), male patient/ fe-
male donor v. other, CMV negative v. seropositive, HLA-C
mismatch, type and status of disease, conditioning regimen (TBI
v. no TBI), source of stem cells (marrow v. PBSC), mean cyclospor-
ine trough levels during the first months (. /\median 220ng/ml),
graft cell count in PBSC (. /\ ] median 7.5x106 CD34/kg). In
multivariate analyses advanced disease was a negative factor for
aGvHD III-IV (HR 5 2.1, p 5 0.018), DFS (HR 1.7, p 5 0.004),
relapse (HR5 1.7, p 5 0.038), and OS (HR 5 1.9, p5 0.002). Pa-
tient age 40 years or more negatively affected NRM (HR5 1.8. p5
0.041). Interestingly, donor age 40 years or more adversely affected
the risk of aGvHD III-IV (HR5 2.6, p5 0.009), extensive cGvHD
(HR 5 2.1, p 5 0.021) and OS (HR 5 1.7, p 5 0.016), whereas
CMV status, male patient/female donor, HLA-Cmismatch, condi-
tioning, graft source, CD34 count or cyclosporine levels had no in-
fluence.
Conclusion: ATG-F significantly reduces acute and chronic
GvHD. By choosing younger donors outcome can be improved in
unrelated donor transplantation.32
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Interleukin 21 (IL-21) is a pro-inflammatory cytokine produced
by Th17 helper T cells, and abrogation of IL-21 signaling has re-
cently been shown to reduce GVHD while retaining GVL. How-
ever, mechanisms by which IL-21 may lead to a separation of
GVHD and GVL are incompletely understood. To characterize
its effect on GVH and GVL T cell responses, we compared
wild type (WT) and IL-21 receptor knockout (IL-21R KO) donor
T cells in a C57BL/6 into BALB/c murine MHC-mismatched
bone marrow transplant (BMT) model. Lethally irradiated BMT
recipients of IL-21R KO T cells demonstrated decreased
GVHD-related morbidity (p\ .05) and mortality (p\ .01) and
decreased histopathologic evidence of GVHD within the small
bowel (p\ .05). While this reduced GVHD was associated with
increased donor regulatory T cells two to three weeks post-
BMT (p \ .001), transplanting selected T cell subsets indicated
that IL-21 signaling in both donor CD4 and CD8 T cells contrib-
uted to GVHD mortality (CD4, p\ .01; CD8, p\ .05), although
effects on CD8 T cells occurred only in the presence of CD4s.
KO and WT donor T cells demonstrated equivalent alloactiva-
tion, as evidenced by proliferation (p \ .001), upregulation of
CD25 (p \ .001), and downregulation of CD62L (p \ .01 for
CD8 T cells) in allogeneic vs. syngeneic recipients. However,
IL-21R KO T cells demonstrated decreased infiltration within
the small bowel (p \ .05) and mesenteric lymph nodes (MLN;
CD8, p\ .05; CD4, p\ .001), and decreased inflammatory cyto-
kine-producing CD4 T cells within MLN (IFN-g, p\ .01; TNF-
a, p\ .001). Consistent with this, transplanted IL-21R KO donor
T cells demonstrated decreased expression of a4b7 integrin
(LPAM, p \ .05), a molecule known to be involved in homing
of GVHD-mediating donor T cells to the gut. However, in con-
trast to the reduced inflammatory cytokine-producing CD4 T
cells observed in MLN, IL-21R KO helper T cell cytokine pro-
duction was maintained in spleen and peripheral lymph nodes,
and IL-21R KO T cells were able to protect recipient mice
from lethality due to A20 lymphoma (p\ .001). In summary, ab-
rogation of IL-21 signaling in donor T cells leads to tissue-spe-
cific modulation of immunity, such that gastrointestinal GVHD
is reduced, but peripheral T cell function and GVL capacity are
retained. Targeting IL-21 for therapeutic intervention is an excit-
ing strategy to separate GVHD from GVL, and this novel ap-
proach should be considered for clinical investigation to
improve transplant outcomes and prevent malignant relapse.33
REG3a IS A BIOMARKER OF GRAFT VERSUS HOST DISEASE OF THE
GASTROINTESTINAL TRACT
Harris, A.C.1, Ferrara, J.L.M.1, Levine, J.E.1, Braun, T.1, Hogan, J.2,
Crawford, J.1, Pitteri, S.2, Wang, H.2, Chin, A.2, Zhang, Q.2,
Granger, J.1, Vander Lugt, M.1, Byersdorfer, C.1, Magenau, J.1,
Gomez, A.1, Choi, S.1, Kitko, C.1, Yanik, G.1, Peres, E.1,
Pawarode, A.1, Mineishi, S.1, Reddy, P.1, Couriel, D.R.1, Hanash, S.2,
Paczesny, S.1 1University of Michigan, Ann Arbor,MI; 2Fred Hutchinson
Cancer Research Center, Seattle, WA
There are no validated plasma biomarkers specific to graft versus
host disease (GVHD) of the gastrointestinal (GI) tract. We have pre-
viously identified and validated elafin as a plasma biomarker for skin
GVHD(ScienceTranslMed, 2:50-57).Using an unbiased proteomics
